Mont-Saint-Aignan, France
Mont-Saint-Aignan, France

The University of Rouen is a French university, in the Academy of Rouen. Wikipedia.


Time filter

Source Type

GENFIT: CONVENING NOTICE TO THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS MEETING ON JUNE 16, 2017 Lille (France), Cambridge (Massachusetts, United States), May 12, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that it has published today in today's French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary and Extraordinary Shareholders' Meeting to be held on Friday, June 16, 2017 at 10:30 am at the University of Lille College of Pharmaceutical and Biological Science located at Parc Eurasanté, 3, rue du Professeur Laguesse in Lille (59000), France. As indicated in its press release on April 24, the shareholders will be invited to vote on the change in the type of administration of the Company, moving from a two-tiered board (Supervisory Board and Executive Board) to a single board structure (Board of Directors). The Company considers that this change will allow it to be closer to international standards and to welcome the expert board members whom it wishes to recruit to accompany its development in the years to come. The Ordinary and Extraordinary Shareholders' Meeting will also be the occasion to implement the provisions of the "Copé-Zimmermann" law (relating to the balanced representation of men and women on corporate boards), and the shareholders will vote on the proposed nomination of Ms. Catherine Larue and Ms. Anne-Hélène Monsellato as directors of the Company.  Additional biographical information, including the experience and expertise of these candidates in included below. As also indicated in the April 24, 2017 press release, and subject to the approval of the shareholders of the change in the type of administration of the Company and the composition of the new Board of Directors, the current Chairman of the Executive Board is proposed to be appointed Chairman of the Board of Directors and Chief Executive Officer of the Company. In addition to the usual items on the agenda related to the review of the financial statements and the different reports of the Executive and Supervisory Boards and the Statutory Auditors for the 2016 fiscal year, the Executive Board is proposing a certain number of alternative draft resolutions that differ depending on the decision of the shareholders with respect to the change in type of administration of the Company.  Depending on this decision, only those draft resolutions relating to the specific type of administration chosen will be submitted to a vote of the shareholders. The resolutions submitted to the shareholders are grouped together in the following manner: Additional information is available in the convening notice dated May 12, 2017, which is available on the Company's website.  All of the documentation concerning the Ordinary and Extraordinary Shareholders' Meeting (including the Say on Pay report pursuant to the Sapin II Law) will be made available to shareholders in accordance with current regulations and also available on the Company's website by May 19, 2017. Dr. Catherine Larue has been CEO ad interim of Luxembourg Institute of Health (LIH), a biomedical research institute, since January 2016. From 2012 to end 2015, she was CEO of the Integrated Biobank of Luxembourg (IBBL), where she led the development of the biobanking strategy and new initiatives in the field of personalized medicine. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at Genfit until 2012. Dr. Catherine Larue began her career as team leader at Sanofi at the Montpellier, France based R&D center in the cardiovascular research department.  She later joined Sanofi Diagnostics Pasteur Inc., in Minnesota, United States, where she ran the immunology department for three years, developing tests and instruments.  She thereafter returned to Paris, France as Director at Sanofi Diagnostics Pasteur, and then spent 11 years at the Bio-Rad group, holding different management positions.  She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products. Dr. Catherine Larue is the author of 85 articles and has filed 13 patents.  She holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John's University (New York).  In 2014, she was voted Luxembourg's most inspiring woman of the year in the "Science, Technology and Research" category. Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management. Since May 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels.  In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. During her time at EY, she gained extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector. Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013. GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2016 Registration Document registered with the French Autorité des marchés financiers on April 28, 2017 under n° R.17-034, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


GENFIT: CONVENING NOTICE TO THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS MEETING ON JUNE 16, 2017 Lille (France), Cambridge (Massachusetts, United States), May 12, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that it has published today in today's French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary and Extraordinary Shareholders' Meeting to be held on Friday, June 16, 2017 at 10:30 am at the University of Lille College of Pharmaceutical and Biological Science located at Parc Eurasanté, 3, rue du Professeur Laguesse in Lille (59000), France. As indicated in its press release on April 24, the shareholders will be invited to vote on the change in the type of administration of the Company, moving from a two-tiered board (Supervisory Board and Executive Board) to a single board structure (Board of Directors). The Company considers that this change will allow it to be closer to international standards and to welcome the expert board members whom it wishes to recruit to accompany its development in the years to come. The Ordinary and Extraordinary Shareholders' Meeting will also be the occasion to implement the provisions of the "Copé-Zimmermann" law (relating to the balanced representation of men and women on corporate boards), and the shareholders will vote on the proposed nomination of Ms. Catherine Larue and Ms. Anne-Hélène Monsellato as directors of the Company.  Additional biographical information, including the experience and expertise of these candidates in included below. As also indicated in the April 24, 2017 press release, and subject to the approval of the shareholders of the change in the type of administration of the Company and the composition of the new Board of Directors, the current Chairman of the Executive Board is proposed to be appointed Chairman of the Board of Directors and Chief Executive Officer of the Company. In addition to the usual items on the agenda related to the review of the financial statements and the different reports of the Executive and Supervisory Boards and the Statutory Auditors for the 2016 fiscal year, the Executive Board is proposing a certain number of alternative draft resolutions that differ depending on the decision of the shareholders with respect to the change in type of administration of the Company.  Depending on this decision, only those draft resolutions relating to the specific type of administration chosen will be submitted to a vote of the shareholders. The resolutions submitted to the shareholders are grouped together in the following manner: Additional information is available in the convening notice dated May 12, 2017, which is available on the Company's website.  All of the documentation concerning the Ordinary and Extraordinary Shareholders' Meeting (including the Say on Pay report pursuant to the Sapin II Law) will be made available to shareholders in accordance with current regulations and also available on the Company's website by May 19, 2017. Dr. Catherine Larue has been CEO ad interim of Luxembourg Institute of Health (LIH), a biomedical research institute, since January 2016. From 2012 to end 2015, she was CEO of the Integrated Biobank of Luxembourg (IBBL), where she led the development of the biobanking strategy and new initiatives in the field of personalized medicine. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at Genfit until 2012. Dr. Catherine Larue began her career as team leader at Sanofi at the Montpellier, France based R&D center in the cardiovascular research department.  She later joined Sanofi Diagnostics Pasteur Inc., in Minnesota, United States, where she ran the immunology department for three years, developing tests and instruments.  She thereafter returned to Paris, France as Director at Sanofi Diagnostics Pasteur, and then spent 11 years at the Bio-Rad group, holding different management positions.  She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products. Dr. Catherine Larue is the author of 85 articles and has filed 13 patents.  She holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John's University (New York).  In 2014, she was voted Luxembourg's most inspiring woman of the year in the "Science, Technology and Research" category. Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management. Since May 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels.  In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. During her time at EY, she gained extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector. Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013. GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2016 Registration Document registered with the French Autorité des marchés financiers on April 28, 2017 under n° R.17-034, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


GENFIT: CONVENING NOTICE TO THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS MEETING ON JUNE 16, 2017 Lille (France), Cambridge (Massachusetts, United States), May 12, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that it has published today in today's French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary and Extraordinary Shareholders' Meeting to be held on Friday, June 16, 2017 at 10:30 am at the University of Lille College of Pharmaceutical and Biological Science located at Parc Eurasanté, 3, rue du Professeur Laguesse in Lille (59000), France. As indicated in its press release on April 24, the shareholders will be invited to vote on the change in the type of administration of the Company, moving from a two-tiered board (Supervisory Board and Executive Board) to a single board structure (Board of Directors). The Company considers that this change will allow it to be closer to international standards and to welcome the expert board members whom it wishes to recruit to accompany its development in the years to come. The Ordinary and Extraordinary Shareholders' Meeting will also be the occasion to implement the provisions of the "Copé-Zimmermann" law (relating to the balanced representation of men and women on corporate boards), and the shareholders will vote on the proposed nomination of Ms. Catherine Larue and Ms. Anne-Hélène Monsellato as directors of the Company.  Additional biographical information, including the experience and expertise of these candidates in included below. As also indicated in the April 24, 2017 press release, and subject to the approval of the shareholders of the change in the type of administration of the Company and the composition of the new Board of Directors, the current Chairman of the Executive Board is proposed to be appointed Chairman of the Board of Directors and Chief Executive Officer of the Company. In addition to the usual items on the agenda related to the review of the financial statements and the different reports of the Executive and Supervisory Boards and the Statutory Auditors for the 2016 fiscal year, the Executive Board is proposing a certain number of alternative draft resolutions that differ depending on the decision of the shareholders with respect to the change in type of administration of the Company.  Depending on this decision, only those draft resolutions relating to the specific type of administration chosen will be submitted to a vote of the shareholders. The resolutions submitted to the shareholders are grouped together in the following manner: Additional information is available in the convening notice dated May 12, 2017, which is available on the Company's website.  All of the documentation concerning the Ordinary and Extraordinary Shareholders' Meeting (including the Say on Pay report pursuant to the Sapin II Law) will be made available to shareholders in accordance with current regulations and also available on the Company's website by May 19, 2017. Dr. Catherine Larue has been CEO ad interim of Luxembourg Institute of Health (LIH), a biomedical research institute, since January 2016. From 2012 to end 2015, she was CEO of the Integrated Biobank of Luxembourg (IBBL), where she led the development of the biobanking strategy and new initiatives in the field of personalized medicine. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at Genfit until 2012. Dr. Catherine Larue began her career as team leader at Sanofi at the Montpellier, France based R&D center in the cardiovascular research department.  She later joined Sanofi Diagnostics Pasteur Inc., in Minnesota, United States, where she ran the immunology department for three years, developing tests and instruments.  She thereafter returned to Paris, France as Director at Sanofi Diagnostics Pasteur, and then spent 11 years at the Bio-Rad group, holding different management positions.  She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products. Dr. Catherine Larue is the author of 85 articles and has filed 13 patents.  She holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John's University (New York).  In 2014, she was voted Luxembourg's most inspiring woman of the year in the "Science, Technology and Research" category. Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management. Since May 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels.  In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. During her time at EY, she gained extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector. Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013. GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2016 Registration Document registered with the French Autorité des marchés financiers on April 28, 2017 under n° R.17-034, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


Patent
University of Rouen | Date: 2017-01-04

The invention relates to a double-porosity three-dimensional material comprising a support consisting of a polymer having a surface which comprises positive charges and is functionalised by bioactive molecules which comprise negative charges and are used to increase the proliferation of eukaryotic cells. It also relates to the production method thereof, and to the uses of same for fixing and stimulating the proliferation of eukaryotic cells.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: LCE-02-2014 | Award Amount: 6.15M | Year: 2015

Prime objective of the Sharc25 project is to develop super-high efficiency Cu(In,Ga)Se2 (CIGS) solar cells for next generation of cost-beneficial solar module technology with the world leading expertise establishing the new benchmarks of global excellence. The project partners ZSW and EMPA hold the current CIGS solar cell efficiency world records of 21.7% on glass and 20.4% on polymer film, achieved by using high (~650C) and low (~450C) temperature CIGS deposition, respectively. Both have developed new processing concepts which open new prospects for further breakthroughs leading to paradigm shift for increased performance of solar cells approaching to the practically achievable theoretical limits. In this way the costs for industrial solar module production < 0.35/Wp and installed systems < 0.60/Wp can be achieved, along with a reduced Capex < 0.75/Wp for factories of >100 MW production capacity, with further scopes for cost reductions through production ramp-up. In this project the performance of single junction CIGS solar cells will be pushed from ~21% towards 25% by a consortium with multidisciplinary expertise. The key limiting factors in state-of-the-art CIGS solar cells are the non-radiative recombination and light absorption losses. Novel concepts will overcome major recombination losses: combinations of increased carrier life time in CIGS with emitter point contacts, engineered grain boundaries for active carrier collection, shift of absorber energy bandgap, and bandgap grading for increased tolerance of potential fluctuations. Innovative approaches will be applied for light management to increase the optical path length in the CIGS absorber and combine novel emitter, front contact, and anti-reflection concepts for higher photon injection into the absorber. Concepts of enhanced cell efficiency will be applied for achieving sub-module efficiencies of >20% and industrial implementation strategies will be proposed for the benefit of European industries.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.93M | Year: 2016

Industries are in need of highly skilled academically trained experts and powerful sets of tools enabling the design, control & prediction of optimized & efficient production process of future high-value products such as chiral pharmaceuticals. The CORE Network will in parallel train 15 ESRs and develop tools, approaches and methods within the area of Continuous Resolution (CORE), the process to obtain enantiopure molecules of chiral compounds. The training objective of the CORE network is to deliver a CORE skills toolbox of knowledge, personal, organizational and impact skills to a core of multi-disciplinary scientists and engineers in the interdisciplinary and cross-sectional field of Continuous Resolution. Each ESR obtains dedicated training through their research project, network events, a webinar course, management involvement and an academic & industrial secondment. The research objective of the CORE Network is to jointly construct a CORE Industrial Toolbox on Continuous Resolution that provides next generation tools, approaches and methods to industry for the development continuous resolution processes. The strongly involved industrial partners will ensure that the CORE Industrial Toolbox fulfils their requirements in the skills gap areas Towards Continuous, Hybrid Resolution and Enabling Resolution. CORE brings together 8 academic and 7 industrial partners resulting in an unparalleled combination of chirality, synthesis and crystallization training and research covering the areas of Chemical Engineering, Chemistry and Applied Physics.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-CSA | Phase: Fission-2013-2.1.1 | Award Amount: 10.28M | Year: 2013

Preparing NUGENIA for HORIZON 2020 The objective of the NUGENIA\ project is to support the NUGENIA Association in its role to coordinate and integrate European research on safety of the Gen II and III nuclear installations in order to better ensure their safe long term operation, integrating private and public efforts, and initiating international collaboration that will create added value in its activity fields. The project consists of two parts, the first part being a Coordination and Support Action and the second part a Collaborative Project. The aim of the first part, the Coordination and Support Action, is to establish an efficient, transparent and high quality management structure to carry out the planning and management of R&D including project calls, proposal evaluation, project follow-up dissemination and valorisation of R&D results in the area of safety of existing Gen II and future Gen III nuclear installations. The preparatory work will encompass governance, organizational, legal and financial work, as well as the establishment of annual work plans, with the aim to structure public-public and/or private-public joint programming enabling NUGENIA to develop into the integrator of the research in the respective field in Europe. The management structure will build on the existing organisation of the NUGENIA Association, currently grouping over 70 nuclear organisations from research and industry (utilities, vendors and small and medium enterprises) active in R&D. In the second part, the Collaborative project, one thematic call for research proposals will be organized among the technical areas of plant safety and risk assessment, severe accident prevention and management, core and reactor performance, integrity assessment of systems, structures and components, innovative Generation III design and harmonisation of procedures and methods. The call will take place one year after the start of the project. The call will implement the priorities recognised in the NUGENIA Roadmap, in line with the Sustainable Nuclear Energy Technology Platform (SNETP) and International Atomic Energy Agency (IAEA) strategies. The research call which is going to be organised within the project is open to all eligible organisations. The NUGENIA\ project will benefit from the experience of the NUGENIA Association member organisations on managing national research programmes and from the track record of the NUGENIA project portfolio.


According to the World Health Organisation (WHO, ADI), 44 million people around the world have some form of dementia, for which there is no effective intervention, to halt or reverse the progressive cognitive impairment. As Europes population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this transition healthcare policies in the EU and individual Member States are heavily focussed on extending the independent life of the elderly, with the dual aim of increasing their quality of life and reducing the costs of care. In this project, we will build a mHealth application that is specifically targeted to caregivers and patients with mild to moderate dementia. The result is CAREGIVERSPRO-MMD: a tool integrating a broader diagnostic approach, incorporating the live-in family caregiver-patient dyad and considering this dyad as the unit of care. CAREGIVERSPRO-MMD will provide value-added services based on social networks, tailored interventions, clinical strategies and gamification for improving quality of life for dementias patients and caregivers that allow them to live in the community for as long as possible. The project will comprise three phases: first, we will develop new services for patients with mild to moderate dementia and their respective caregivers to an existing application. In the second phase, we will conduct a user-centric analysis to re-design the existing application for patients with mild to moderate dementia. The development will be steered by patients, carers and doctors, through user-centric design: we will collect feedback on each new version of the application until the design is adapted to the users needs. In the third phase, we will pilot the optimised application with 550 dyads (patients and their respective caregivers) and 550 controls. This will show the clinical and social benefits for patients and caregivers, as well as financial benefits for the healthcare system.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2014-ETN | Award Amount: 3.73M | Year: 2015

The physical and psychosocial impact of armed conflict on children is immense and particularly so, if these children are associated with the enemy. Overwhelming evidence suggests that children born of war (CBOW), i.e. children fathered by foreign soldiers and born to local mothers have been and continue to be a major obstacle to successful integration of both their mothers and themselves into post-conflict societies. At a global level, previous UN studies have further emphasized the lack of research on children born out of forced pregnancies in armed conflict. The proposed network addresses the described shortcomings by advancing the knowledge base through systematic analysis of lived experiences of CBOW in a variety of 20th century conflict and post-conflict situations. The main research goal is to further our understanding of how (if at all) CBOW in conflict and post-conflict situations are integrated into society; how (if at all) militaries, governments, and nongovernmental policy makers assist this integration process; and how the childrens lived experiences reflect broader societal attitudes to memories of war and vice versa. Our vision is to promote scientific excellence by exploiting the specific research expertise and infrastructure of the co-ordinating partner and all participants in order to advance the research competencies and employability of early career researchers. Their enhanced understanding of the challenges of CBOW in volatile societies will inform the normative debates and, ultimately, policies on the reintegration of CBOW into post-conflict societies. By combining historical, social empirical, psychiatric, political, legal, memory, public health and development studies with the discourse surrounding currently enacted humanitarian intervention, insights gained from this network will surpass existing knowledge and will help improve on current integration efforts.


Coquerel G.,University of Rouen
Chemical Society Reviews | Year: 2014

The aim of the tutorial review is to show that any crystallization from solution is guided by stable or metastable equilibria and thus can be rationalized by using phase diagrams. Crystallization conducted by cooling, by evaporation and by anti-solvent addition is mainly considered. The driving force of crystallization is quantified and the occurrence of transient metastable states is logically explained by looking at the pathways of crystallization and the progressive segregation which might occur in a heterogeneous system. This journal is © the Partner Organisations 2014.

Loading University of Rouen collaborators
Loading University of Rouen collaborators